[1] BRANSWELL H, JOSEPH A. WHO declares the coronavirus outbreak a pandemic[EB/OL].(2020-03-11)[2023-06-15]. https://www.statnews.com/2020/03/11/who-declares-the-coronavirus-outbreak-a-pandemic.
[2] 仲宣惟, 韩若斯, 李波. 中美应对突发公共卫生事件医药产品应急政策分析与思考[J]. 中国药学杂志, 2020, 55(23):1979-1984. doi:  10.11669/cpj.2020.23.013
[3] 李峰, 何辉. 新形势下药品监管科学的内涵与发展[J]. 中国新药杂志, 2019, 28(16):1921-1925. doi:  10.3969/j.issn.1003-3734.2019.16.001
[4] FDA. Emergency Use Authorization[EB/OL].(2020-02-18) [2023-06-15]. https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization.
[5] FDA. Emergency Use Authorization-Archived Information [EB/OL].(2023-05-31)[2023-06-15]. https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization-archived-information.
[6] 国家基因科学数据中心. 2019新型冠状病毒数据库 [EB/OL].(2020-01-30) [2023-06-10]. https://ngdc.cncb.ac.cn/?lang=zh.
[7] TRAN A, WITEK T J Jr. The emergency use authorization of pharmaceuticals: history and utility during the COVID-19 pandemic[J]. Pharm Med, 2021, 35(4):203-213. doi:  10.1007/s40290-021-00397-6
[8] Bloch EM, Shoham S, Casadevall A, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19[J]. J Clin Invest,2020,130(6): 2757-2765.
[9] MARKS P W, MARSTON H D, BADEN L R. End of a declared public health emergency—implications for U. S. emergency use authorizations[J]. N Engl J Med, 2023, 388(13):1153-1155. doi:  10.1056/NEJMp2300392
[10] ZUCKERMAN D M. Emergency use authorizations(EUAs)versus FDA approval: implications for COVID-19 and public health[J]. Am J Public Health, 2021, 111(6):1065-1069. doi:  10.2105/AJPH.2021.306273
[11] CASSIDY C, DEVER D, STANBERY L, et al. FDA efficiency for approval process of COVID-19 therapeutics[J]. Infect Agent Cancer, 2020, 15(1):73. doi:  10.1186/s13027-020-00338-z
[12] KHEHRA N, PADDA I, JAFERI U, et al. Tozinameran (BNT162b2) vaccine: the journey from preclinical research to clinical trials and authorization[J]. AAPS Pharmscitech, 2021, 22(5):172. doi:  10.1208/s12249-021-02058-y
[13] SHARFSTEIN J M, GOODMAN J L, BORIO L. The US regulatory system and COVID-19 vaccines[J]. JAMA, 2021, 325(12):1153. doi:  10.1001/jama.2021.1961
[14] 杨悦. 美国药品监管科学研究[M]. 北京: 中国医药科技出版社, 2020.
[15] 德、法、意等国暂停使用阿斯利康疫苗. 人民网[EB/OL]. (2021-03-16)[2023-06-15]. http://world.people.com.cn/n1/2021/0316/c1002-32053006.html.